423 related articles for article (PubMed ID: 19519432)
1. Scientific and clinical challenges in sepsis.
Ulloa L; Brunner M; Ramos L; Deitch EA
Curr Pharm Des; 2009; 15(16):1918-35. PubMed ID: 19519432
[TBL] [Abstract][Full Text] [Related]
2. Experimental therapeutic strategies for severe sepsis: mediators and mechanisms.
Parrish WR; Gallowitsch-Puerta M; Czura CJ; Tracey KJ
Ann N Y Acad Sci; 2008 Nov; 1144():210-36. PubMed ID: 19076379
[TBL] [Abstract][Full Text] [Related]
3. Novel insights for systemic inflammation in sepsis and hemorrhage.
Cai B; Deitch EA; Ulloa L
Mediators Inflamm; 2010; 2010():642462. PubMed ID: 20628562
[TBL] [Abstract][Full Text] [Related]
4. The neuronal strategy for inflammation.
Ulloa L; Wang P
Novartis Found Symp; 2007; 280():223-33; discussion 233-7. PubMed ID: 17380797
[TBL] [Abstract][Full Text] [Related]
5. Sepsis Care Pathway 2019.
Labib A
Qatar Med J; 2019; 2019(2):4. PubMed ID: 31763206
[No Abstract] [Full Text] [Related]
6. Treatment of severe sepsis: where next? Current and future treatment approaches after the introduction of drotrecogin alfa.
Rice TW
Vasc Health Risk Manag; 2006; 2(1):3-18. PubMed ID: 17319465
[TBL] [Abstract][Full Text] [Related]
7. HMGB1 as a therapeutic target for sepsis: it's all in the timing!
Gentile LF; Moldawer LL
Expert Opin Ther Targets; 2014 Mar; 18(3):243-5. PubMed ID: 24479494
[TBL] [Abstract][Full Text] [Related]
8. Novel HMGB1-inhibiting therapeutic agents for experimental sepsis.
Wang H; Ward MF; Sama AE
Shock; 2009 Oct; 32(4):348-57. PubMed ID: 19333143
[TBL] [Abstract][Full Text] [Related]
9. Lack of evidence for qualitative treatment by disease severity interactions in clinical studies of severe sepsis.
Macias WL; Nelson DR; Williams M; Garg R; Janes J; Sashegyi A
Crit Care; 2005; 9(6):R607-22. PubMed ID: 16280057
[TBL] [Abstract][Full Text] [Related]
10. Targeting HMGB1 in the treatment of sepsis.
Wang H; Ward MF; Sama AE
Expert Opin Ther Targets; 2014 Mar; 18(3):257-68. PubMed ID: 24392842
[TBL] [Abstract][Full Text] [Related]
11. Reversing established sepsis with antagonists of endogenous high-mobility group box 1.
Yang H; Ochani M; Li J; Qiang X; Tanovic M; Harris HE; Susarla SM; Ulloa L; Wang H; DiRaimo R; Czura CJ; Wang H; Roth J; Warren HS; Fink MP; Fenton MJ; Andersson U; Tracey KJ
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):296-301. PubMed ID: 14695889
[TBL] [Abstract][Full Text] [Related]
12. [Advances in high mobility group box-1 protein mediated multiple organ dysfunction and its potential interventional strategies].
Yao YM; Xu S; Sheng ZY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2007 Aug; 29(4):459-65. PubMed ID: 19209785
[TBL] [Abstract][Full Text] [Related]
13. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
14. The enigma of sepsis.
Riedemann NC; Guo RF; Ward PA
J Clin Invest; 2003 Aug; 112(4):460-7. PubMed ID: 12925683
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in the pathophysiology and molecular basis of sepsis-associated organ dysfunction: Novel therapeutic implications and challenges.
Hattori Y; Hattori K; Suzuki T; Matsuda N
Pharmacol Ther; 2017 Sep; 177():56-66. PubMed ID: 28232275
[TBL] [Abstract][Full Text] [Related]
16. Bench to bedside: HMGB1-a novel proinflammatory cytokine and potential therapeutic target for septic patients in the emergency department.
Sama AE; D'Amore J; Ward MF; Chen G; Wang H
Acad Emerg Med; 2004 Aug; 11(8):867-73. PubMed ID: 15289194
[TBL] [Abstract][Full Text] [Related]
17. Clinical trial design and outcomes in patients with severe sepsis.
Opal SM
Shock; 2003 Oct; 20(4):295-302. PubMed ID: 14501941
[TBL] [Abstract][Full Text] [Related]
18. Role of high mobility group box 1 in inflammatory disease: focus on sepsis.
Bae JS
Arch Pharm Res; 2012 Sep; 35(9):1511-23. PubMed ID: 23054707
[TBL] [Abstract][Full Text] [Related]
19. New and emerging therapies for sepsis.
Healy DP
Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
